Fatal Outcomes of Concurrent Tuberculosis and COVID-19 Discovered

Research revealed that during a pandemic cohort study, almost one in three adults aged 45 and above who had both tuberculosis and COVID-19 passed away.

Individuals aged 45 and above with both tuberculosis and COVID-19 had a mortality rate of almost 30% during a pandemic cohort study in NYC.

The study team modeled the long-term clinical and economic impact of two-dose universal varicella vaccination (UVV) strategies in Denmark using a dynamic transmission model.

Conjunctivitis: An Emerging Symptom of COVID-19 in Infants
COVID-19 and conjunctivitis (pink eye) in infants: The sudden rise in COVID-19 cases in India has put infants at a higher risk of developing eye problems like conjunctivitis.

‘Pandemic cohort study found that almost one in three adults aged 45 and above who had both tuberculosis and COVID-19 died between March 2020 and June 2022.’

The cost-effectiveness of UVV was evaluated along with the impact on varicella (including age shift) and herpes zoster burden. Six two-dose UVV strategies were compared to no vaccination, at either short (12/15 months) or medium (15/48 months) intervals.

Monovalent vaccines (V-MSD or V-GSK) for the 1st dose, and either monovalent or quadrivalent vaccines (MMRV-MSD or MMRV-GSK) for the 2nd dose were considered.

Investigating the Deadliness of Tuberculosis and COVID-19

Compared to no vaccination, all two-dose UVV strategies reduced varicella cases by 94%-96%, hospitalizations by 93%-94%, and deaths by 91%-92% over 50 years; herpes zoster cases were also reduced by 9%.

Moderna and Pfizer-BioNTech Vaccines Get Green Light for Second COVID-19 Booster
FDA revises the emergency use authorizations for the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines for those with compromised immune systems.

Moreover, there was a decline in the total number of annual varicella cases in all age groups including adolescents and adults.

All UVV strategies were cost-effective compared to no vaccination, with ICER values ranging from €18,228-€20,263/QALY (payer perspective) and €3,746-€5,937/QALY (societal perspective).

Gut Bacteria Suppresses Immune Responses To COVID-19 Vaccine
New study assesses the human gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity.

The frontier analysis showed that a two-dose strategy with V-MSD (15 months) and MMRV-MSD (48 months) dominated all other strategies and was the most cost-effective.

In conclusion, all modeled two-dose UVV strategies were projected to substantially reduce the clinical and economic burden of varicella disease in Denmark compared to the current no-vaccination strategy, with declines in both varicella and zoster incidence for all age groups over a 50-year time horizon.

Source-Eurekalert